New Insights into the Use of Cytotoxic Agents for Cancer Treatment

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 4608

Special Issue Editor


E-Mail Website
Guest Editor
Department of Oncology, Jagiellonian University Medical College, 31-007 Cracow, Poland
Interests: metronomic chemotherapy; geriatric oncology; combined treatment modalities; novel therapeutic targets; breast cancer; ovarian cancer; prostate cancer; RCC; urothelial cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Chemotherapy has been used for more than 70 years for the treatment of cancer. However, its modern use in clinical practice is very different to its use even 20 years ago. With the use of antibody–drug conjugates, chemo-immunotherapy, and chemoradiotherapy, a totally new era of cancer treatment has recently begun. This Special Issue is aimed at collecting and summarizing the recent advances in novel applications of chemotherapy in clinical practice and in clinical trials.
I welcome submissions regarding:

  • Novel antibody–drug conjugates
  • The use of antibody–drug conjugates in:
    • Breast cancer
    • Urothelial cancer
  • Chemoimmunotherapy in:
    • Breast cancer
    • Lung cancer
    • Head and neck cancer
    • Gastric cancer
  • Novel cytotoxic agents
  • Novel strategies of treatment with cytotoxic agents as metronomic chemotherapy
  • Breast cancer
  • Ovarian cancer
  • Gastrointestinal cancers
  • Brain tumors
  • Novel predictive factors for chemotherapy

I look forward to receiving your contributions.

Dr. Piotr J. Wysocki
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antibody-drug conjugates
  • metronomic chemotherapy
  • chemoimmunotherapy
  • sacituzumab govitecan
  • trastuzumab emtansine
  • trastuzumab deruxtecan
  • enfortumab vedotin
  • solid tumors
  • breast cancer
  • ovarian cancer

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

12 pages, 1815 KiB  
Article
Metronomic Chemotherapy Based on Topotecan or Topotecan and Cyclophosphamide Combination (CyTo) in Advanced, Pretreated Ovarian Cancer
by Piotr J. Wysocki, Mateusz Łobacz, Paweł Potocki, Łukasz Kwinta, Anna Michałowska-Kaczmarczyk, Agnieszka Słowik, Kamil Konopka and Anna Buda-Nowak
Cancers 2023, 15(4), 1067; https://doi.org/10.3390/cancers15041067 - 7 Feb 2023
Cited by 11 | Viewed by 1886
Abstract
Patients with advanced ovarian cancer (OC) have a detrimental prognosis. The options for systemic treatment of advanced OC in later lines of treatment are limited by the availability of active therapies and their applicability to often fragile, exhausted patients with poor performance status. [...] Read more.
Patients with advanced ovarian cancer (OC) have a detrimental prognosis. The options for systemic treatment of advanced OC in later lines of treatment are limited by the availability of active therapies and their applicability to often fragile, exhausted patients with poor performance status. Metronomic chemotherapy (MC) is a concept of a continuous administration of cytotoxic drugs, which is characterized by multidirectional activity (anti-proliferative, anti-angiogenic, and anti-immunosuppressive) and low toxicity. We have performed a retrospective analysis of consecutive, advanced, chemo-refractory OC patients treated with MC based on single-agent topotecan (1 mg p.o. q2d) or on a topotecan (1 mg q2d) and cyclophosphamide (50 mg p.o. qd) combination (CyTo). Metronomic chemotherapy demonstrated promising activity, with 72% and 86% of patients achieving biochemical or objective disease control and 18% and 27% of patients achieving a biochemical or objective response, respectively. The median PFS in the whole population was 3.65 months, but the median PFS in patients with a biochemical response to MC (18.2% of patients) reached 10.7 months. The study also suggested that overweight or obese patients had significantly better outcomes on MC than patients with BMI <25 kg/m2. This article is the first report in the literature on metronomic chemotherapy based on a topotecan + cyclophosphamide combination (CyTo). The CyTo regimen demonstrated safety, clinical activity, and potential broad clinical applicability in advanced OC patients and will be evaluated in a forthcoming clinical trial. Full article
(This article belongs to the Special Issue New Insights into the Use of Cytotoxic Agents for Cancer Treatment)
Show Figures

Figure 1

Review

Jump to: Research

17 pages, 321 KiB  
Review
Recent Therapeutic Advances in Gynecologic Oncology: A Review
by Elise M. Wilson, Ramez N. Eskander and Pratibha S. Binder
Cancers 2024, 16(4), 770; https://doi.org/10.3390/cancers16040770 - 13 Feb 2024
Viewed by 2129
Abstract
Gynecologic malignancies have high incidence rates both nationally and internationally, and cervical, endometrial, and ovarian cancers account for high mortality rates worldwide. Significant research is ongoing to develop targeted therapies to address unmet needs in the field and improve patient outcomes. As tumors [...] Read more.
Gynecologic malignancies have high incidence rates both nationally and internationally, and cervical, endometrial, and ovarian cancers account for high mortality rates worldwide. Significant research is ongoing to develop targeted therapies to address unmet needs in the field and improve patient outcomes. As tumors mutate and progress through traditional lines of treatment, new therapies must be developed to overcome resistance and target cancer-specific receptors and mutations. Recent advances in the development of immunotherapy and antibody–drug conjugates have resulted in compelling and clinically meaningful results in cervical, endometrial, and ovarian cancers. In the last decade, several immunotherapy agents have received FDA approval or NCCN guideline recommendation for the treatment of gynecologic malignancies, including dostarlimab for advanced or recurrent endometrial cancer and pembrolizumab for advanced or recurrent cervical and endometrial cancers. Several other immunotherapeutic agents are under active investigation. Development of antibody–drug conjugates including tisotumab vedotin in cervical cancer, mirvetuximab soravtansine in ovarian cancer, and trastuzumab deruxtecan in multiple gynecologic cancers has translated into exciting efficacy signals, prompting full drug approvals and additional investigation. This article aims to review recent novel advances in targeted treatments for gynecologic malignancies, highlighting the trials and data underlying these novel interventions. Full article
(This article belongs to the Special Issue New Insights into the Use of Cytotoxic Agents for Cancer Treatment)
Back to TopTop